

1646
\$
a/g
1/28
4/14/00
RECEIVED
APR 19 2000
TC 1600 MAIL ROOM


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Moore et al.

Application Serial No.: 09/376,430

Filed: August 18, 1999

For: **Cytokine Receptor Common
Gamma Chain Like**



Art Unit: 1646

Examiner: O'Hara, E.

Attorney Docket No.: PF466P1

PROVISIONAL ELECTION UNDER 37 C.F.R. § 1.143
WITH TRAVERSE AND AMENDMENT UNDER 37 C.F.R. § 1.111

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action dated March 15, 2000, applicants provisionally elect, *with traverse*, Group II represented by newly added claims 24 to 101, for further prosecution. Applicants reserve the right to file one or more divisional applications directed to the non-elected inventions should the restriction requirement be made final. Submitted concurrently herewith are (a) a Fee Transmittal Sheet; and (b) an Information Disclosure Statement together with Form PTO 1449.

In the Specification:

Please amend the specification as follows:

On page 8, line 20, please delete "between nucleotides 256 and 277".

On page 13, line 24, please replace "presence" with --present--.

On page 60, line 27, please replace "immuno" with --immunogenic--.

In the Claims:

Please cancel claims ~~2-12~~, ~~14-16~~ and ~~20-21~~ without prejudice and add the following new claims:

Am --24. (New) An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:

04/18/2000 NHARHOL 00000148 003425 09376430

01 FC:103 1116.00 CH

02 FC:102 546.00 CH